Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome

By sjmartinez • October 5, 2022

Gaylis NB, Ritter A, Kelly SA, Pourhassan NZ, Tiwary M, Sacha JB, Hansen SG, Recknor C, Yang OO. Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome. Clin Infect Dis. 2022 Sep 30;75(7):1232-1234. doi: 10.1093/cid/ciac226. PMID: 35452519; PMCID: PMC9383814.

Tags: CCR5, immunosuppression, Infectious Diseases, leronlimab, long COVID, Publications

Pitavastatin effects on lipids in relation to major adverse cardiovascular events: a REPRIEVE secondary analysis

Umbleja T, Zafar MU, McCallum S, Gattu AK, Zanni MV, Bloomfield GS, Malvestutto CD, Fichtenbaum CJ, Currier JS, Sponseller CA, Diggs MR, Chu SM, Lu[...]

Non-canonical IL-22 receptor signaling remodels the oral mucosal barrier during Candida albicans immunosurveillance

Millet N, Sekar J, Solis NV, Miao J, Millet A, Aggor FEY, Wildeman A, Cook ME, Davari A, Peters BM, Lionakis MS, Gaffen SL, Jendzjowsky[...]

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Baricitinib vs. Tocilizumab

Nadig N, Bhimraj A, Cawcutt K, Chiotos K, Dzierba AL, Kim AY, Martin GS, Pearson JC, Shumaker AH, Baden LR, Bedimo R, Cheng VC, Chew[...]